Advertisement

Topics

Protalex Provides Update on US and EU Studies of PRTX-100 to Treat Immune Thrombocytopenia

08:00 EST 21 Feb 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Expanding Number of Clinical Sites in US and EU; Underscoring Growing Interest in PRTX-100 among Clinical Investigators Protalex, Inc. (OTCQB:PRTX), a clinical-stage biopharmaceutical company, today provides an update on its...

Other Sources for this Article

LHA
Anne Marie Fields, 212-838-3777
afields@lhai.com

NEXT ARTICLE

More From BioPortfolio on "Protalex Provides Update on US and EU Studies of PRTX-100 to Treat Immune Thrombocytopenia"

Advertisement
Quick Search
Advertisement
Advertisement